Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

Why did Warren Buffett step down from Berkshire Hathaway? How will Trump's 100% foreign film tariffs impact Hollywood? What caused Tesla's stock decline in Europe? Why are states suing Trump over wind energy policies? How is the Fed likely to act on interest rates this week? What are the effects of OPEC+ increasing oil production? How will Apple’s App Store fee ruling appeal affect developers? Why is Skechers being taken private amid trade tensions? What is the impact of student loan collections resuming?

Lantern Advances Breast Cancer Drug Candidate With FDA Clearance For Early-Stage Trial

benzinga.com/general/biotech/25/05/45192281/exclusive-lantern-advances-breast-cancer-drug-candidate-with-fda-clearance-for-early-stage-trial

The U.S. Food and Drug Administration (FDA) on Monday cleared Lantern Pharma Inc.’s (NASDAQ:LTRN) Investigational New Drug Application (IND) for a Phase 1b/2 trial for LP-184 in triple-negative breast cancer (TNBC).
The dual approach in the clinical trial is designed to evaluate LP-184 in…

This story appeared on benzinga.com, 2025-05-05 12:31:48.